The journey from unmet need in allergic rhinitis to rationale for, and clinical development of, a new treatment option, MP29-02

• Currently considered first-line allergic rhinitis (AR) therapy provides insufficient symptom relief for many AR patients. • MP29-02 (Dymista®, Meda AB, Solna, Sweden) is a new intranasal AR therapy, consisting of azelastine hydrochloride (AZE) and fluticasone propionate (FP) in a novel and patented formulation and advanced device. • It is indicated for the symptomatic relief of moderate/severe seasonal AR and perennial AR in patients 12 years and older where monotherapy with either intranasal antihistamine or intranasal corticosteroid is not considered sufficient. • MP29-02 is twice as effective as FP and AZE for the relief of nasal and ocular symptoms in seasonal AR patients and provides more complete symptom control days faster. • Its novel formulation and improved device contribute to this superiority. • Superiority of MP29-02 over FP was confirmed in patients with chronic rhinitis (i.e., perennial AR or non-AR) and is sustained for 1 year. • MP29-02 is well tolerated both short and long term. • MP29-02 should be considered first-line therapy for all moderate/severe AR patients in consultation with their clinicians, since current first-line therapy may be considered inadequate for the majority of them.